Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
M.Alonso-AriasR
doi: 10.1186/s13023-021-01732-5 139 TohPNicholsonJLVetterAMBerryMJTorresDJ
& Stickel, F
Other in vitro studies on human erythrocytes have assessed the induction of eryptosis by OPFRs such as tris(2-chloroethyl) phosphate (TCEP) and tris(1-chloro-2-propyl) phosphate (TCPP)
in December 2024 the FDA's Pharmacy Compounding Advisory Committee voted against adding it to the final 503A bulks list, citing nonclinical toxicity, an unresolved cardiac signal, and immunogenicity risk
US$ 23.03
US$ 20.09
US$ 22.13
US$ 24.38
US$ 24.97
-guide-detail.jpg?v=1722502564)
